Lupin peers

·Pharma & HealthChart ›

Companies like Lupinlatest year

LupinLUPIN · FY26 · this company
Market cap₹90,192
P/E16.90×
Sales growth+32.0%
ROE26.9%
Sun Pharmaceutical IndustriesSUNPHARMA · FY26
Open ›
Market cap₹4,21,677
P/E36.77×
Sales growth+10.5%
ROE14.7%
CiplaCIPLA · FY26
Open ›
Market cap₹1,10,313
P/E28.43×
Sales growth−2.4%
ROE11.8%
Dr. Reddy's LaboratoriesDRREDDY · FY26
Open ›
Market cap₹1,11,506
P/E26.49×
Sales growth−1.5%
ROE11.8%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LUPIN₹1,972.70

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹90,192 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
LUPIN
FY26
SUNPHARMA
FY26
CIPLA
FY26
DRREDDY
FY26
Peer
Average
Valuation — at last close
P/E◆ 16.90×36.77×28.43×26.49×30.56× -45%
P/B4.02×5.05×3.20×◆ 2.94×3.73× +8%
EV/EBITDA◆ 9.86×22.19×17.28×17.19×18.89× -48%
Market Cap₹90,192 Cr₹4.22L Cr₹1.10L Cr₹1.12L Cr₹2.14L Cr -58%
Growth
Revenue CAGR 3Y◆ 18.88%10.03%7.37%10.96%9.45% +100%
Revenue CAGR 5Y◆ 13.02%11.78%8.01%12.09%10.63% +23%
Net Income CAGR 3Y◆ 128.70%10.57%10.88%-2.66%6.26% +1955%
Revenue YoY (latest Q)◆ 32.04%10.46%-2.44%-1.48%2.18% +1370%
Net Income YoY (latest Q)16.01%◆ 26.53%-37.08%-31.69%-14.08% +214%
Profitability
EBITDA Margin◆ 31.53%30.33%20.89%19.15%23.46% +34%
Net Income Margin19.16%◆ 19.69%13.71%12.34%15.25% +26%
Return on Common Equity◆ 26.90%14.74%11.82%11.75%12.77% +111%
Return on Capital Employed◆ 32.38%18.48%13.87%11.30%14.55% +123%
Return on Assets◆ 15.85%11.46%9.67%7.73%9.62% +65%
Credit & Quality
Total Debt/Equity0.26×0.05×◆ 0.01×0.16×0.07× +255%
Interest Coverage17.12×43.65×◆ 85.90×11.76×47.10× -64%
Scale — latest FY
Revenue / Total Income₹27,958 Cr₹58,462 Cr₹28,163 Cr₹33,700 Cr₹40,108 Cr -30%
Net Income₹5,355 Cr₹11,509 Cr₹3,862 Cr₹4,158 Cr₹6,509 Cr -18%
Total Assets₹38,365 Cr₹1.09L Cr₹42,496 Cr₹58,123 Cr₹69,802 Cr -45%
EPS₹116.75₹47.8₹48.03₹50.41₹48.75 +140%
Book Value per Share₹490.99₹348.31₹426.24₹453.79₹409.45 +20%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.